Orphan Disease

Oncology

We have successfully delivered more than 16 pre-clinical oncology projects, utilising our Integrated Drug Discovery expertise to develop small molecule drug candidates to treat a variety of cancers such as leukaemia, breast and prostate cancer. From initial screening and profiling through to clinically relevant Biomarkers, our DMPK and bioscience group can provide full support for your discovery projects.

Diabetes

Diabetes is a metabolic disorder that is an increasingly prevalent disease worldwide.  We have established assays to support the investigation of diabetic therapies including functional assays to quantify insulin and Glucagon-Like Protein (GLP-1) secretion, as well as glucose transport. We also have access to tissue and blood from in vivo diabetic models through strategic collaborations.

Neuroscience

Our scientists have a well-developed understanding of the challenges associated with the design and optimisation of compounds that target the central nervous system (CNS). Our experience is both broad, reaching across a number of neurodegenerative diseases (such as Alzheimer’s, Parkinson’s and Amyotrophic Lateral Sclerosis) and neuropathic pain, and deep-rooted, with members of our senior team having 10+ years in CNS drug research.

Orphan Disease

Sygnature’s team of scientists have a strong track record of adding value to client projects in the field of rare and orphan diseases.  Sygnature’s advanced intellectual input and established relationships with providers of diseased tissue allows rapid progression of projects in this challenging therapeutic area.

Respiratory

We have an excellent track record of success in the field of respiratory diseases using our extensive in-house expertise, accelerating 5 compounds to the clinic and a further 4 into preclinical development for our clients. Our collaborative approach to drug discovery and our established network of KOLs in the field have been invaluable to the progression of our clients’ projects

Immuno-oncology

Modulation of the immune system presents an exciting new approach for the therapeutic perturbation of cancer cell growth. Sygnature have developed a comprehensive platform to study the processes involved in immuno-oncology, including the assessment of cytokines, intracellular signalling, T-cell proliferation assays and antibody-dependent cell cytotoxicity (ADCC) assays.

Anti-Infectives

Sygnature have a history of enabling discovery success in the field of anti-infectives. Our Medicinal Chemistry and Computational Chemistry teams have worked in close collaboration with many clients to design potent and efficacious compounds, resulting in the delivery of two preclinical candidates. Our Bioscience team can provide cytopathic effect and viability screening assays to assess compounds designed to inhibit virus attachment, entry or replication in human host cells.

Inflammation and Immunology

Our scientists have a rich heritage in this therapeutic area and provide significant experience in developing in vitro assays utilising Peripheral Blood Mononuclear Cells (PBMCs), T lymphocytes (e.g. CD4+/CD8+), leukocytes, and phagocytes, amongst others, that assess various inflammation and immunological biomarkers, processes, and endpoints.